Funding & Business initiatives

Boosting innovation throughout the Hadassah biomedical ecosystem
Hadasit develops and executes novel funding models and initiatives that provide hands on business guidance to support technologies originating in the Hadassah University Medical Center and the greater Hadassah biomedical ecosystem

Bio-Holdings Ltd.

Hadasit Bio-Holdings Ltd. (HBL) was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) to allow public participation in academically originated biotechnology innovations.
It is a precedent-setting model. For the first time, the public can invest in companies based on IP generated by the Hadassah University Hospital. HBL traded shares are a unique vehicle for investing in a portfolio of biotech companies all based on inventions developed and owned by Hadassah

NGT HealthCare
II incubator

Hadasit has partnered with the NGT HealthCare II
venture capital fund to establish a $30M incubator fund
backed by the Israel Innovation Authority, to support
seed-stage startups, from Hadassah and elsewhere,
and bridge the gap between academia and industry.

Azrieli college
of engineering

Hadasit is the technology transfer company for Azrieli College’s healthcare-related intellectual property. We bring together Hadassah’s clinical experts and the best engineering minds at Azrieli to create viable new projects in various fields: including bio convergence, bioengineering, medical device and more. 

Hadassah researchers interested in collaboration with Azrieli college engineers are welcome to contact VP of Medical Device Business Development at Hadasit


Jerusalem BioPark, Hadassah Ein Kerem POB 12000, Jerusalem 91120, Israel
Tel. +972-2-6778757 Fax. +972-2-6437712 Email.